The merger and corporate makeover represent a fresh start for Mallinckrodt and Endo, which have both faced significant financial pressure in recent years over their alleged roles in the opioid. Listening for Needs, Delivering Solutions | Mallinckrodt Pharmaceuticals combined with Endo in 2025 to better serve customers and improve outcomes for the patients we support. This site is an online medical resource intended to provide scientifically accurate, evidence-based, and balanced medical information on Mallinckrodt products. Mallinckrodt looks like it could join Purdue Pharma in reaching a settlement in its bankruptcy proceedings related to opioid litigation, after years of legal wrangling. Transaction Info MNK Pro Forma Net Sales and Adjusted EBITDA Information Q3 2025 MNK Pro Forma Net Sales and Adjusted EBITDA Information Q2 2025 Mallinckrodt-Endo Transaction FAQs Process for Transferring Shares MNK Redemption Notice Private-Side Bond Holder Information Access Mallinckrodt and Endo are merging to create a leading global therapeutics company with branded and generic products. Stay tuned for updates. Mallinckrodt is a global specialty pharmaceutical business that develops, manufactures, markets and distributes specialty pharmaceutical products. The area of focus is neonatal critical care respiratory therapies. Our Products With 150 years of experience in solving complex challenges, we at Mallinckrodt Pharmaceuticals believe in producing high-quality specialty pharmaceuticals. Learn More Our Products Producing high-quality, specialty treatments INOmax® Learn More Product Monograph Mallinckrodt Pharmaceuticals plc is an Irish-American manufacturer of specialty pharmaceuticals (namely, adrenocorticotropic hormone), generic drugs and imaging agents. [2] In 2017, it had 5,500 employees and sales of $3.2 billion, of which $2.9 billion was from the U.S. healthcare system. [3].